Form PTO-1449 U.S. DEPARTMENT OF COMMER					ATTY. DOCKET NO. SERIAL NO.			
OFFICE		P	ATENT AND TR	ADEMARK	2836-D		09/44	18,378
lucc	20114	TION DIOOLO	oune Ci	TATION!	APPLICANT	1		
INFC	JHIVIA	TION DISCLO	SURE CI	TATION	Brasel et al.			
					FILING DATE GROUP /644			644
	(Use	several sheets i	f necessar	/)	November 23, 1999 — 1636			
				U.S. PATEN	T DOCUMENTS			
EXAMINER	0	OCUMENT NUMBER	DATE		NAME CLASS SUB		SUBCLASS	FILING DATE IF APPROPRIATE
B	4	,745,099	05/17/88	Akamatsu e	t al.	_		
	5	,013,824	05/07/91	Abrams et a	l.			
	5	,057,420	10/15/91	Massey, Jos	eph M. E JC23	-		
	5	,061,620	10/29/91	Tsukamoto	et al. 1 2000 g	/ <		
	5	,114,710	05/19/92	Takaku e al	. FEB ROS	_		
	5	,116,964	5/26/92	Capon et al.	PATENT & TRADERA			
	5	,185,438	02/09/93	Lemischka,	Ihor R.	_		
	5	,192,553	03/9/93	Boyse et al.		_		-
	5	,199,942	04/6/93	Gillis, Steve	n			
	5	,270,458	12/14/93	Lemischka,	Ihor R.			
			F	OREIGN PATI	ENT DOCUMENTS			
	D	OCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
R	V	VO 92/18615	10/29/92	PCT				
1	V	VO 93/08268	04/29/93	PCT		_	4-1	
	2	,163,105	05/18/94	CA		_		
	0	627 487 A2	05/19/94	EP		_		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
Stanley, E. R. et al., "CSF-1-A Mononuclear Phagocyte Lineage-Specific Hemopoietic Growth Factor," <i>J. Cell. Bio. 21</i> :151-159, 1983.								
7	Y. Yarden and A. Ullrich, "Growth Factor Receptor Tyrosine Kinases," Ann. Rev. Biochem. 57:443-478, 1988.							
EXAMINE	EXAMINED DATE CONSIDERED 7/12/00							
EXAMINE	R: Initia	I if citation consider	ed, whether	or not citation is	in conformance with MPE	P 609;	Draw line throu	gh citation if
not in conformance and not considered. Include copy of this form with next communication to applicant.								

Sried 2 or 9							
Form P			OF COMMERCE	ATTY, DOCKET NO. SERIAL NO.			
OFFICE	F	PATENT AND TR	ADEMARK	2836-D		09/4	48,378
INFO	RMATION DISCLO	SURE CI	TATION	APPLICANT			
				Brasel et al.			
	(Use several sheets	if necessar	y)	November 23, 19	99	GROUP /	644
			U.S. PATEN	IT DOCUMENTS			
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS	FILING DATE
R	5,283,354	02/01/94	Lemischka,	Thor B	_	_	
	5,326,558	07/05/94	Turner et al	3000			
	5,367,057	11/22/94	Lemischke	POTR. 2000	_		
	5,397,706	03/14/95	Correa Carl	MT & TRANCIMAT	~	-	
	5,399,493	03/21/95	Emerson et	al.	-		
	5,437,994	08/01/95	Emerson et	al.			
	5,453,357	09/26/95	Hogan, Brig	gid L. M.			
	5,459,069	10/17/95	Palsson et a	l.			
	5,525,708	06/11/96	Nocka et al.		_		
	5,548,065	08/20/96	Lemischka,	Ihor R.	_	+	
	5,554,512	09/10/96	Lyman et al	Lyman et ai.		$\perp$	
		F	OREIGN PAT	ENT DOCUMENTS			
	DOCUMENT NUMBER	DATE		COUNTRY	CLAS	SUBCLASS	TRANSLATION YES NO
R	WO 94/26891	11/24/94	PCT				
	WO 94/28391	12/08/94	PCT		_		
	WO 95/00554	01/05/95	PCT		-	_	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
R	J. G. Flanagan and P. Leder, "The kit Ligand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts," Cell 63:185-194, 1990.						
1		D. Cadena and G. Gill, "Receptor tyrosine kinases," FASEB 6:2332-2337, 1992.					
EXAMINER	8 J. N. 1	110	4	DATE CONSIDERED 7/12	1/00	> >	
*EXAMINEF	R: Initial if citation consider	red, whether	of not citation is	in conformance with MPE	P 609;	Draw line throu	gh citation if
not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 U.S. DEPARTMENT OF COMMERC				ATTY, DOCKET NO. SERIAL NO.			
OFFICE	F	PATENT AND TR	ADEMARK	2836-D		09/4	48,378
INFO	RMATION DISCLO	SURE CI	TATION	APPLICANT Brasel et al.		L	
				FILING DATE		GROUP	144
	(Use several sheets	if necessar	y)	November 23, 1	999	Í.	536
		U.S. PATEN	NT DOCUMENTS	.,			
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLASS	FILING DATE IF APPROPRIATE
R	5,843,423	12/01/98	Lyman et al		-	#	
	5,627,025	05/06/97	Steinman et	al.		00	
	5,635,388	06/03/97	Bennett et a	il. FEB	7 20	0 2	
				PATEM	1 4	, nat	
					1		
					T		
				•	+		
				<del></del>	+		
J		F	OREIGN PAT	ENT DOCUMENTS			
	DOCUMENT NUMBER	DATE		COUNTRY	CLAS	S SUBCLASS	TRANSLATION YES NO
R	WO 93/20186	10/14/93	PCT		T-		
	0 563 485 A1	03/30/92	EP		T-	_	
	WO 96/00779	01/11/96	PCT		_	-	
-	OTHER DO	CUMENTS	(Including Aut	thor. Title, Date, Pertine	ent Pages.	. Etc.)	
R	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Matthews, W. et al., "A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations," Cell 65:1143-1152, 1991.						
	Lyman, S. D. et al., "Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene," <i>Oncogene</i> 8:815-822, 1993.						
	Rosnet, O. et al., "Isolation and Chromosomal Localization of a Novel FMS-like Tyrosine Kinase Gene," <i>Genomics</i> 9:380-385, 1991.						
EXAMINER	T.R. M	1 0/1		DATE CONSIDERED 7/	12/	00	
EXAMINE	R: Initial if citation consider	red, whether	or not citation is	in conformance with Mi	PEP 609;	Draw line throu	gh citation if
not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form P	TO	1449 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.			
OFFICE		PATENT AND TRADEMARK	2836-D	09/448,378			
002							
INFO	ORM	ATION DISCLOSURE CITATION	APPLICANT				
			Brasel et al.				
1			FILING DATE	GROUP 1/UV			
		(Supplemental Sheet)	November 23, 1999	1636			
L		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent Page:	s, Etc.)			
1 4	1	Lyman, Stewart D. et al., "Molecular Cl	oning of a Ligand for the fl	t3/flk-2 Tyrosine Kinase			
19	1	Receptor: A Proliferative Factor for Pri 1993.	mitive Hematopoietic Cells	," Cell 75:1157-1167,			
<del></del>		Maroc, N. et al., "Biochemical character	rization and analysis of the	transforming notantial of			
OF	١.	the PLT3/FLK2 receptor tyrosine kinase	"Oncogene 8.909-918 10	u anstorning potential of			
OIPE	1 00	S W	, Oneogene 0.707 510, 17	<i>33</i> .			
1 1	1 10	Birt F. et al., "Expression of the FMS/F	XIT-Like Gene FLT3 in Hu	nan Acute Leukemias of			
28	1	the Myeloid and Lymphoid Lineages," I	Blood 80 (10):2584-2593, 1	992.			
460,	ļ.,	der.					
PATENT	& TRA	Dosil, M. et al, "Mitogenic Signalling ar					
	1	Tyrosine Kinase in Fibroblasts and Inter	leukin 3-Dependent Hemat	opoietic Cells," Mol. And			
<del></del>	Cell. Biol. 13(10):6572-6585 1993.  Hannum, C. et al., "Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of						
	1	haematopoietic stem cells and is encode					
	}		,,,				
		Broxmeyer, H. E. et al., "Commentary:	A Rapid Proliferation Assa	y for Unknown Co-			
1	1	Stimulating Factors in Cord Blood Plast					
1	}	Expansion and Replating Capacity of Hu	uman Hematopoietic Stem/I	Progenitor Cells," Blood			
<del></del>		Cells 20:492-497, 1994. de Vries, P. et al., "The Effect of the FL"	T2 I in and On Described Man	in Division to the			
	}	Hematopoietic Stem Cells," J. of Cell. B	iochem Sunni 18h:177 ab	stract #H110 1004			
		Thematopolede Stem Cons, 3. by Cen. B	юспет. вирри 100.177, ио	su acc #11110, 1994.			
		Rossner, M. T. et al., "Fms-like Tyrosine	e Kinase 3 Catalytic Domai	n Can Transduce a			
		Proliferative Signal in FDC-P1 Cells Th.		the Signal Delivered by			
		c-Fms <sup>1</sup> ," Cell Growth & Differentiation					
		Small, D. et al., "STK-1, the human hom					
		CD34* human bone marrow cells and is cells," <i>Proc. Natl. Acad. Sci. USA 91</i> :45		i of early progenitor/stem			
	-	Zeigler, F. C. et al., "Cellular and Molec	ular Characterization of the	Role of the FLK-2/FLT-			
		3 Receptor Tyrosine Kinase in Hematop	oietic Stem Cells," Blood 8	4(8):2422-2430, 1994.			
		de Vries, P. et al., "The Role of FLT3 Li	gand in Early Murine Hem	atopoiesis," Blood 84(10)			
	Suppl. 1:279a, abstract #1100, 1994.						
	do Vrigo P et al. "The Effects of Calable TI TO Linear On Marie TV."						
	de Vries, P. et al., "The Effects of Soluble FLT3 Ligand On Murine Pluripotent Hematopoietic Stem Cells," Experimental Hematology 22(8):724, abstract #174, 1994.						
		Lapertment	м 11стиноноду 22(0).124, а	υσα αυτ π174, 1774.			
		Stewart, F. M. et al., "Post-5-Fluorourac	il Human Marrow: Stem C	ell Characteristics and			
		Renewal Properties After Autologous M	arrow Transplantation," Blo	ood 81(9):2283-2289,			
- L	لـــــ	1993					
EXAMINE	1	1/1/1/1/1/1	DATE CONSIDERED				
		Jan Jak / A	7/12/0	0			
*EXAMINE	R: Ini	tial in citation considered, whether or not citation is not and not considered. Include copy of this form	in conformance with MPEP 609;	Draw line through citation if			
		The series of th	non communication to appi	ours.			

	Forn	n PTO-1	449	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.	
	OFFICE			PATENT AND TRADEMARK	2836-D	09/448,378	
	11	NFORM	ATION [	DISCLOSURE CITATION	Brasel et al.	<u> </u>	
	(Supplemental Sheet) OTHER DOCUMENTS (Including Auth			lemental Sheet)	FILING DATE November 23, 1999	GROUP 1644 1636	
				THER DOCUMENTS (Including Au		·	
	R		Bernhar Hemato 55:1099	d, H. et al., "Generation of Imm poietic Progenitor Cells of the B l-1104, 1995.	unostimulatory Dendritic C one Marrow and Peripheral	ells from Human CD34+ Blood," Cancer Res.	
			Immuno	ee, M. et al., "Idiotypic antibody htherap. 38:75-82. 1994.			
مرة	ш	C33		., "Toward a Genetic Analysis o 211, 1992.	f Tumor Rejection Antigen	s," Adv. Cancer Res.	
ç٤	8.1	To Take	Nat'l Ca	e, G., "New Molecule Under Stu uncer Inst. 89(17):1257, 1997.		·	
PAT	Pulendran, B. et al., "Developmental Pathways of Dendritic Cells in Vivo: Distinct Fun Phenotype, and Localization of Dendritic Cell Subsets in FLT3 Ligand-Treated Mice," <i>Immunol.</i> 159(5):2222-2231, 1997.  Shurin, M. et al., "FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice," Cell. Immunol. 179(2):174-184, 1997.					and-Treated Mice," J.	
						ally Active Dendritic	
				. et al., "Antitumor Activity and Breast Cancer Model," Cancer I			
	Strobl, H. et al., "flt3 Ligand in Cooperation with Transforming Growth Factor-β1 Potentiates In Vitro Development of Langerhans-Type Dendritic Cells and Allows Sin Cell Dendritic Cell Cluster Formation Under Serum-Free Conditions," Blood, 90(4):14 1434, 1997.					ells and Allows Single-	
			Circulat Splenic	et al., "Chronic Expression of Ming White Blood Cell Levels and Fibrosis," <i>Blood 90(1)</i> :76-84, 19	l Abnormal Cellular Infiltra 197.	tes Associated With	
	Lynch, D. et al., "Flt3 ligand induces tumor regression and antitumor immune vivo," Nature Med. 3(6):625-631, 1997.					or immune responses in	
	Saunders, D. et al., "Dendritic Cell Development in Culture from Thymic Precursor Ce the Absence of Granulocyte/Macrophage Colony-stimulating Factor," <i>J. Exp. Med.</i> 184:2185-2196, 1996.						
	Maraskovsky, E. et al., "Dramatic Increase in the Numbers of Functionally Mature Dendr Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified," J. Exp. Med. 184:1953-1962, 1996.						
	E. Sprecher and Y. Becker, "Role of Langerhans cells and other dendritic cells in viral diseases," Arch. Virol. 132:1-28, 1993.						
	EXAMI	2		- Varla Vat	DATE CONSIDERED 7/12/	ao	
	*EXAMINER: Initial fi citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

				`				
	For	m P	TO-	1449 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.		
	OFFIC	E		PATENT AND TRADEMARK	2836-D	09/448,378		
	1							
	1	NF	DRM	ATION DISCLOSURE CITATION	APPLICANT	FEB 1 0 2000		
	1				Brasel et al.	GROUP /////		
				(Supplemental Sheet)	November 23, 1999	1626-		
	<del> </del>					4000		
			1,	OTHER DOCUMENTS (Including Aut Broxmeyer, H. et al., "Flt3 ligand stimul	hor, Title, Date, Pertinent Pages	th ofolaid		
	F	₹/		stem/progenitor cells," Exp. Hematol. 23	3:1121-1129, 1995.	iii oi iiiyeioid		
				A. Porgador and E. Gilboa, "Bone Marror restricted Peptide are Potent Inducers of 260, 1995.				
				Hudak, S. et al., "FLT3/FLK2 Ligand Pr Expansion Of Colony-Forming Cells An 85(10):2747-2755, 1995.	d Spleen Colony-Forming	Units," Blood		
É		JC3		Muench, M. et al., "FLK-2/FLT-3 Ligan Progenitors Isolated From Human Fetal	Liver," <i>Blood 85(4)</i> :963-97	2, 1995.		
•	1	100	OFFICE	Steinman, R., "The Dendritic Cell System and Its Role in Immunogenicity," Annu. Rev. Immunol. 9:271-296, 1991.				
¢&	M & T	bresi	4	Macatonia, S. et al., "Primary proliferati vitro by human dendritic cells," Immuno		oonses to HIV induced in		
210	Pancholi, P. et al., "Dendritic Cells Efficiently Immunoselect Mycobacterial-Reactive In Human Blood, Including Clonable Antigen-Reactive Precursors," <i>Immunology</i> 76: 224, 1992.					bacterial-Reactive T Cells "Immunology 76:217-		
				Inaba, K. et al., "Dendritic Cells Pulsed Specific, MHC-Restricted T Cells In Sitt	With Protein Antigens In V 1," J. Exp. Med. 172:631-64	itro Can Prime Antigen- 40, 1990.		
				Bujdoso, R. et al., "Afferent Lymph Den Presentation In Vivo," Intern. Rev. Immu		Antigen Capture And		
Jaffe, R., "Review Of Human Dendritic Cells: Isolation And Culture Pediatric Pathology 13:821-837, 1993.					e From Precursors,"			
				Bermstein, I. et al., "Isolation Of Human 1994.	•			
	Young, J. et al., "Identification Of Dendritic Cell Colony-Forming Units Among Human CD34" Bone Marrow Progenitors That Are Expanded By C-Kit Ligand 4 Pure Dendritic Cell Colonies In The Presence Of Granulocyte/Macrophage Colo Stimulating Factor And Tumor Necrosis Factor a," J. Exp. Med. 182:1111-1120,							
Inaba, K. et al., "Dendritic Cell Progenitors Phagocytose Particulates, Inc Calmette-Guerin Organisms, And Sensitize Mice To Mycobacterial Anti Exp. Med. 178:479-488, 1993.								
	EXAN		8	J. fally	PATE CONSIDERED, 7/12/00	2		

\*EXAMINER: Initial Metiation considered, widefiner of not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	,		Sheet _7_ of9			
Form PTO		ATTY, DOCKET NO.	SERIAL NO.			
OFFICE	PATENT AND TRADEMARK	2836-D	09/448,378			
INFORM	MATION DISCLOSURE CITATION	APPLICANT	1,,,,			
	without Biodeodorie or without	Brasel et al.				
		FILING DATE	GROUP			
	(Supplemental Sheet)	November 23, 1999	1636			
	OTHER DOCUMENTS (Including A					
	Papayannopoulo et al., "In Vivo Effect					
	Hematopoietic Progenitors in Primates Granulocyte Colony-Stimulating Facto					
	Lotem, J. and Sachs, L., "Control of In					
	Leukemia 2(12 Suppl.):24S-37S, 1988.		Fiora Leukerine Cens,			
	Stewart D. Lyman et al., "Cloning of the	ne Human Homologue of the	Murine flt3 Ligand: A			
	Growth Factor for Early Hematopoietic	c Progenitor Cells," Blood 8.	3(10):2795-2801, 1994.			
	D. Hanahan, "Transgenic Mice as Prob 1989.	es into Complex Systems,"	Science 246:1265-1275,			
JC33	Romani, N. et al., "Proliferating Dendr 180:83-93, 1994.	itic Cell Progenitors in Hum	an Blood," J. Exp. Med.			
Winton, E. F. et al., "Recombinant Human (rh) FLT3 Ligand Plus rhGM-CSF of						
CHICK	Causes a Marked CD34* Cell Mobilization to Blood in Rhesus Monkeys," ASH Abstrac					
& TRA		Sallusto and A. Lanzavecchia, "Efficient Presentation of Soluble Antigen by Cultured				
	Human Dendritic Cells is Maintained b					
1	Factor Plus Interleukin 4 and Downreg 179:1109-1118, 1994.	ulated by Tumor Necrosis Fa	actor $\alpha$ , J. Exp. Med.			
	Szabolcs, P. et al, "Expansion of Immu	nostimulatory Dendritic Cel	ls Among the Myeloid			
İ	Progeny of Human CD34* Bone Marro					
	Granulocyte-Macrophage Colony-Stim 5861, 1995.	,				
	Rosnet, O. et al., "Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family," Oncogene 6:1641-1650, 1991.					
	S. Stengelin et al., "Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning," EMBO J. 7(4):1053-1059, 1988					
	Debets, R. and Savelkoul, H. F. J. "Cytokine antagonists and their potential therapeutic use," Immunol. Today 15(10):455-458, 1994.					
	ne Marrow Enriched for nes," <i>Blood 80</i> , 296a;					
	Reid, D. L. et al., "Interactions Of Tum Colony-Stimulating Factor And Other ( Growth In Vitro From Early Bipotent C	Cytokines In The Regulation	Of Dendritic Cell			
	Immunol. 149(8):2681-2688, 1992.	_				
EXAMINER		DATE CONSIDERED				
EXAMINER: In	itial if citation considered, whether or not citation is ance and not considered. Include copy of this for	s in conformance with MPEP 609;	Draw line through citation if			
not in comoni	ance and not considered. Include copy of this for	ii witii next communication to app	ican.			

Form P	TO-1	449 U.S. DEPARTMENT OF COMMERCE	ATT. DOCKET NO.	SERIAL NO.			
OFFICE		PATENT AND TRADEMARK	2836-D	09/448,378			
INFO	) RM	ATION DISCLOSURE CITATION	APPLICANT				
""	,	A THORN BROOKE CONTROL	Brasel et al.				
			FILING DATE	GROUP /644			
		(Supplemental Sheet)	November 23, 1999	_1636			
		OTHER DOCUMENTS (Including Aut	hor, Title, Date, Pertinent Pages	, Etc.)			
N		Thomson, A. W. et al., "Microchimerism Tolerance," Stem Cells 13:622-639, 1995	5.	•			
		Lyman, S. D. and Jacobsen, S. E. W., "c. Factors With Overlapping Yet Distinct A	Activities," Blood 91(4): 11	01-1134, 1998.			
		Ray, R. J. et al., "Flt3 ligand supports the presence of IL-11 and IL-7," Manuscript	, February 20, 1996.				
	ГСЗЭ	Chklovskaia, E. et al., "Increased Produc Chemotherapy-Induced Bone Marrow Su Meeting of the European Haematology A	uppression," 1996 EHA Ab Association, May 29-June 1	stract Form, Second , 1996.			
1 1		Wodnar-Filipowicz, A. et al., "Tyrosine ariemia," Manuscript, February 20, 1996.		•			
40	Parcel	Hsu, F. et al, "Antigen-Pulsed Dendritic Lymphoma," Abstract # C1-314, Keysto					
PATEN		Drexhage, H. A., "A Defective Maturation Diabetics," Abstract # C1-204, Keystone					
		Fisch, P. et al., "Ex Vivo Generation of F Peripheral Blood CD34' Hematopoietic I 311, Keystone Conference, Taos, NM, M	Progenitor Cells in Cancer I Iarch 1995.	Patients," Abstract # C1-			
		Mayordomo, J. et al., "Bone Marrow-De Peptide-Based Antitumor Vaccines," Abs March 1995.	stract # C1-213, Keystone (	Conference, Taos, NM,			
	Lenz, P. et al., "MHC Class I'/II Dendritic Cells Sensitize for Transplantation Immunity Abstract # C1-318, Keystone Conference, Taos, NM, March 1995.						
	Ye, Z. et al., "Evaluation of Dendritic Cells in Allogeneic Marrow Grafts," Abstract # C1-130, Keystone Conference, Taos, NM, March 1995.						
	Thomson, A. W. et al., "Growth of Donor-Derived Dendritic Cells From the Bone Marrow of Murine Liver Allograft Recipients in Response to Granulocyte/Macrophage Colony-Stimulating Factor," Abstract # C1-125, Keystone Conference, Taos, NM, March 1995.						
	Whalen, R. G. et al., "DNA-Mediated Immunization to the Hepatitis B Surface Antigen: Potential Involvement of Interstitial Dendritic Cells," Abstract # C1-128, Keystone Conference, Taos, NM, March 1995.						
EXAMINER	EXAMINER DATE CONSIDERED 7/12/00						
	*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

• , . •

Form P	TO-1	1449 U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SEHIAL NO.
OFFICE		PATENT AND TRADEMARK	2836-D	09/448,378
			ţ	
INFO	)RM	ATION DISCLOSURE CITATION	APPLICANT	
1			Brasel et al.	
			FILING DATE	GROUP 1644
		(Supplemental Sheet)	November 23, 1999	<del>1636</del>
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent Pages	. Etc.)
		Alters, S. et al., "Characterization and C		
M /		Antigen Presentation, Abstract # C1-30	2, Keystone Conference, Ta	os, NM, March 1995.
10				
		ء د		
		OIPE VC		
		200		
	/	-7 2000 a		
	$\vdash$	LFU X/		
		TENT & TRANCHART		
	٦	TENT & TRAN		
	_			
1				
1				
1	- 1			
ı	- 1			
ł	1			
	_			
1				
ĺ				
1	1			
- 1	1			
1	ł			
	Ì	- /		
EXAMINER		511 1/11/	DATE CONSIDERED /	/ \
	1	I Kan Wash Water	7/12/	00
*EXAMINE	R: Init	ial if citation considered, whether or not citation is	in conformance with MPEP 609:	Draw line through citation if

\*EXAMINER: Initial if citation confidered, whether or not citation is in conformance with MPEP 609; Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.